Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study tests Mirikizumab's power against ulcerative colitis

NCT ID NCT07695636

Completed Disease control Sponsor: IRCCS San Raffaele Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study tracks 282 adults with moderate-to-severe ulcerative colitis who are taking mirikizumab as part of their routine care. Researchers will measure how many achieve clinical remission at 12 weeks and endoscopic remission at 24 and 52 weeks, along with changes in symptoms and inflammation markers. The goal is to see if the drug works as well in real life as it does in clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
mirikizumab
What this could lead to
If successful, this study could confirm that mirikizumab is effective and safe for treating ulcerative colitis in real-world settings, not just in controlled trials.
What could go wrong
This is an observational study, not a controlled experiment, so results may be influenced by other factors. It is also relatively small and short-term, so long-term benefits or rare risks may not be captured.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS (UC)

Contacts and locations

Locations

  • IRCCS San Raffaele

    Milan, Mi, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.